Publications 2022

Løndalen A, Blakkisrud J, Revheim ME, Dahle J, Kolstad A, Stokke C (2022)
FDG PET/CT and Dosimetric Studies of ¹⁷⁷Lu-Lilotomab Satetraxetan in a First-in-Human Trial for Relapsed Indolent non-Hodgkin Lymphoma-Are We Hitting the Target?
Mol Imaging Biol, 24 (5), 807-817
DOI 10.1007/s11307-022-01731-3, PubMed 35486292

Skipar K, Hompland T, Lund KV, Løndalen A, Malinen E, Kristensen GB, Lindemann K, Nakken ES, Bruheim K, Lyng H (2022)
Risk of recurrence after chemoradiotherapy identified by multimodal MRI and 18F-FDG-PET/CT in locally advanced cervical cancer
Radiother Oncol, 176, 17-24
DOI 10.1016/j.radonc.2022.09.002, PubMed 36113778

Publications 2021

Blakkisrud J, Løndalen A, Dahle J, Martinsen AC, Kolstad A, Stokke C (2021)
Myelosuppression in patients treated with ¹⁷⁷Lutetium-lilotomab satetraxetan can be predicted with absorbed dose to the red marrow as the only variable
Acta Oncol, 60 (11), 1481-1488
DOI 10.1080/0284186X.2021.1959635, PubMed 34425735

Publications 2020

Kolstad A, Illidge T, Bolstad N, Spetalen S, Madsbu U, Stokke C, Blakkisrud J, Løndalen A, O'Rourke N, Beasley M, Jurczak W, Fagerli UM, Kaščák M, Bayne M, Obr A, Dahle J, Rojkjaer L, Pascal V, Holte H (2020)
Phase 1/2a study of 177Lu-lilotomab satetraxetan in relapsed/refractory indolent non-Hodgkin lymphoma
Blood Adv, 4 (17), 4091-4101
DOI 10.1182/bloodadvances.2020002583, PubMed 32877524

Løndalen A, Blakkisrud J, Revheim ME, Madsbu UE, Dahle J, Kolstad A, Stokke C (2020)
FDG PET/CT parameters and correlations with tumor-absorbed doses in a phase 1 trial of ¹⁷⁷Lu-lilotomab satetraxetan for treatment of relapsed non-Hodgkin lymphoma
Eur J Nucl Med Mol Imaging, 48 (6), 1902-1914
DOI 10.1007/s00259-020-05098-x, PubMed 33196921

Publications 2019

Bogsrud TV, Londalen A, Brandal P, Leske H, Panagopoulos I, Borghammer P, Bach-Gansmo T (2019)
18F-Fluciclovine PET/CT in Suspected Residual or Recurrent High-Grade Glioma
Clin Nucl Med, 44 (8), 605-611
DOI 10.1097/RLU.0000000000002641, PubMed 31274605

Publications 2018

Stokke C, Blakkisrud J, Løndalen A, Dahle J, Martinsen ACT, Holte H, Kolstad A (2018)
Pre-dosing with lilotomab prior to therapy with ¹⁷⁷Lu-lilotomab satetraxetan significantly increases the ratio of tumor to red marrow absorbed dose in non-Hodgkin lymphoma patients
Eur J Nucl Med Mol Imaging, 45 (7), 1233-1241
DOI 10.1007/s00259-018-3964-9, PubMed 29470615

Publications 2017

Blakkisrud J, Holtedahl JE, Løndalen A, Dahle J, Bach-Gansmo T, Holte H, Nygaard S, Kolstad A, Stokke C (2017)
Biodistribution and Dosimetry Results from a Phase 1 Trial of Therapy with the Antibody-Radionuclide Conjugate ¹⁷⁷Lu-Lilotomab Satetraxetan
J Nucl Med, 59 (4), 704-710
DOI 10.2967/jnumed.117.195347, PubMed 28848035

Publications 2016

Blakkisrud J, Løndalen A, Dahle J, Turner S, Holte H, Kolstad A, Stokke C (2016)
Red Marrow-Absorbed Dose for Non-Hodgkin Lymphoma Patients Treated with 177Lu-Lilotomab Satetraxetan, a Novel Anti-CD37 Antibody-Radionuclide Conjugate
J Nucl Med, 58 (1), 55-61
DOI 10.2967/jnumed.116.180471, PubMed 27587710

Blakkisrud J, Løndalen A, Martinsen AC, Dahle J, Holtedahl JE, Bach-Gansmo T, Holte H, Kolstad A, Stokke C (2016)
Tumor-Absorbed Dose for Non-Hodgkin Lymphoma Patients Treated with the Anti-CD37 Antibody Radionuclide Conjugate 177Lu-Lilotomab Satetraxetan
J Nucl Med, 58 (1), 48-54
DOI 10.2967/jnumed.116.173922, PubMed 27493270

Publications 2015

Berg AS, Løndalen A, Brustugun OT (2015)
[Typical growth pattern in malignant pleural mesothelioma]
Tidsskr Nor Laegeforen, 135 (11), 1050
DOI 10.4045/tidsskr.14.0480, PubMed 26080781

Publications 2014

Bach-Gansmo T, Wien TN, Løndalen A, Halvorsen E (2014)
Myocardial uptake of bone scintigraphic agents associated with increased pulmonary uptake
Clin Physiol Funct Imaging, 36 (3), 237-41
DOI 10.1111/cpf.12219, PubMed 25524030